Zobrazeno 1 - 10
of 1 384
pro vyhledávání: '"Blockades."'
Publikováno v:
Drug Design, Development and Therapy, Vol Volume 18, Pp 4135-4151 (2024)
Ming Bai,1,* Wei-Xue Wang,1,2,* Ting Deng,1 Jing-Jing Duan,1 Yi Ba1,3 1Department of Gastrointestinal Medical Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of
Externí odkaz:
https://doaj.org/article/353b7244833f4f6d970e296b0af2ec44
Publikováno v:
International Journal of General Medicine, Vol Volume 17, Pp 3627-3640 (2024)
Wei Sun,1,* Yun Liu,2,* Li Wang3 1Department of Oncology, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, People’s Republic of China; 2Department of Medical Oncology, National Cancer Center/National Clinical Research Ce
Externí odkaz:
https://doaj.org/article/6e69bce861434d4e97e48687e8fd9ab7
Publikováno v:
Biomolecules & Biomedicine (2024)
Immune checkpoint inhibitors produce durable antitumor effects in various cancers, but not all patients respond. High tumor mutational burden (TMB) is a known predictor of clinical benefit. In this study, we focused on the MHC-I-dependent neoantigen
Externí odkaz:
https://doaj.org/article/fafcced7d135481cbc92ac08bc8da603
Publikováno v:
Advanced Science, Vol 11, Iss 41, Pp n/a-n/a (2024)
Abstract The programmed death 1 (PD‐1)/programmed death ligand 1 (PD‐L1) axis inhibits T cell activity, impairing anti‐tumor immunity. Blocking this axis with therapeutic antibodies is one of the most promising anti‐tumor immunotherapies. It
Externí odkaz:
https://doaj.org/article/87d266990ffa4fdeb0e793dd8cd90150
Publikováno v:
Lung Cancer: Targets and Therapy, Vol Volume 15, Pp 29-40 (2024)
Xue-Jun Dou,1,* Run-Yang Ma,1,* De-Wang Ren,1 Qiang Liu,2 Peng Yan3 1Department of Thoracic Surgery, Aerospace Center Hospital, Beijing, 100049, People’s Republic of China; 2Department of Thoracic Surgery, Peking University International Ho
Externí odkaz:
https://doaj.org/article/e02352716d8940d59a5a94e8615c2660